Table 2 Patient characteristics
From: Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity
DL 4, 5A, 5B ( n =17) | Ovarian cancer ( n =19 a , all DLs) | |
|---|---|---|
Characteristics | Value | |
Age, years | ||
Median | 60 | 52.5 |
Range | 37–74 year old | 40–61 year old |
No. of patients | 17 | 19 |
ECOG performance status | ||
0 | 5 | 1 |
1 | 12 | 18 |
Sex | ||
Female | 14 | 19 |
Male | 3 | 0 |
Previous anticancer treatments | ||
All, median (range) | 3 (1–7) | 5 (1–11) |
Chemotherapy, median (range) | 2 (1–7) | 4 (1–9)b |
Radiation, median (range) | 1 (1–5) | 0 |
Tumour type | N=17 | |
Ovarian cancer | 6 | 19a |
Uterine | 3 | |
Cervical | 2 | |
Breast | 2 | |
Melanoma | 1 | |
Sarcoma | 1 | |
Basal cell cancer | 1 | |
Urothelial cancer | 1 | |
